Latest Industry Trends & News
Recently Added
Catalyst OrthoScience Publishes Study Results for Total Shoulder System
Catalyst OrthoScience announced May 9 that results of a study on its Catalyst CSR total shoulder system were published in the Journal of Shoulder and Elbow Arthroplasty. The CSR system is unique be...
Novel Approaches to Cataract Surgery are Challenging Phaco; Cost May Determine Their Success
Ultrasonic phacoemulsification (USP) has been the dominant method of cataract surgery globally over the past half century, but novel alternative approaches are attempting to improve or replace it. ...
Second Sight to Focus on Orion, Suspend Production of Argus II
.png)
Second Sight Medical Products announced May 15 that it plans to accelerate development and commercialization of its Orion Visual Cortical Prosthesis System, a device implanted in the brain, and sus...
Bausch + Lomb’s Q1-2019 Revenues Increase 1 Percent to $1.12 billion
.jpg)
Bausch + Lomb posted revenues of $1.12 billion in Q1-2019, a 1 percent increase (+7 percent in constant currency) over Q1-2018 revenues of $1.10 billion. The New Jersey-based eye care segment of Ba...
US FDA Expands Labeling for Regeneron’s Eylea to All Stages of DR
Regeneron’s Eylea has gained US approval for the added indication of all stages of diabetic retinopathy, the company announced May 13. The VEGF inhibitor previously was labeled for diabetic retinop...
Harrow Health’s Q1-2019 Revenues Increase 39 Percent
Harrow Health reported May 9 that its Q1-2019 revenues totaled $12.3 million, a 39 percent increase over Q1-2018 revenues of $8.9 million. The San Diego drug developer and compounder attributed the...
BVI Appoints Shervin Korangy as President, CEO
Ophthalmic device maker BVI Medical announced May 16 that it has appointed Shervin Korangy as president and chief executive officer. Korangy replaces Dana Mead Jr., who will continue to serve as vi...
BioTime Receives New $2.5 Million Grant to Advance OpRegen
.png)
BioTime announced May 10 that it has received a $2.5 million grant from the Israel Innovation Authority to continue development of OpRegen. OpRegen is a retinal pigment epithelium transplant therap...
Livionex Raises $4M in Series A to Advance Candidates for Cataracts, Other Diseases
Livionex Pharma announced May 13 that is raised $4 million in a Series A round to advance its treatments for cataracts, gum disease, and herpes simplex virus. The San Francisco company said it is s...
Kala Reports Q1-2019 Revenues of $1.4 Million for Inveltys
Kala Pharmaceuticals reported May 9 that its Q1-2019 revenues for Inveltys totaled $1.4 million. Inveltys was launched in January 2019. Inveltys is a combination of Kala’s AMPPLIFY drug delivery te...
Applied Therapeutics Raises $40M in IPO; Pipeline Includes Topical Candidate for DR
Applied Therapeutics raised $40 million in its initial public offering and began trading May 14 on the Nasdaq Global Market under the symbol APLT. The New York company priced 4 million shares at $1...
CollPlant Trial Results Show Receptor-Optimized BMP-2 Composite Is Preferable to Standard of Care
CollPlant reported April 24 that results from its study of receptor-optimized BMP-2/6/Activin in a ceramic and rhCollagen matrix were published in Science Translational Medicine. Bioventus created ...
Past News Stories
Relievant Releases 24-Month Results for SMART Trial
Relievant Medsystems announced April 24 that it has published 24-month results for its SMART Trial in the International Journal of Spine Surgery. Of 128 patients in the trial, 106 completed the 24-...
US FDA Approves Naloxone Nasal Spray
According to an April 19 press release, the FDA approved a generic naloxone nasal spray. Naloxone is commonly known by the brand name Narcan; it is used to combat narcotic overdoses. The generic sp...
Novartis to Acquire Xiidra From Takeda for up to $5.3 Billion
.png)
Novartis announced May 9 that it will acquire the dry eye drug Xiidra from Japanese drug maker Takeda. Switzerland-based Novartis will pay $3.4 billion up front, plus up to $1.9 billion in mileston...
Orthopedic US 510(k) Clearances
.png)
Stimwave received FDA clearance at the end of March for an update to its Freedom spinal cord stimulator system to include pulse widths of 30 µs to 1000 µs and high frequency stimulation in the rang...
Heritability Study of Knee OA
.png)
A recent study examined the heritability of knee osteoarthritis (OA) among twins. OA is a degenerative joint disease, and it is a primary inciting factor for joint replacement surgery. Knee OA has ...
2019 APSS Annual Meeting
.png)
Over 600 attendees convened at the Songdo Convensia in Incheon, South Korea, for the joint meeting of the Asia Pacific Spine Society (APSS) and Asia Pacific Pediatric Orthopaedic Society (APPOS). T...
Jury Trial Begins in Allergan’s Suit of Imprimis Pharmaceuticals over Compounding
A California jury will decide whether Allergan has suffered monetary harm from Imprimis Pharmaceuticals’ compounding of ophthalmic drugs. US District Judge David O. Carter is overseeing the trial, ...
FDA to End Alternative Summary Reporting Program for Device-Related Injuries
The US FDA announced May 2 that it is ending the alternative summary reporting program for all medical devices. The program allowed device makers to report adverse events to a database inaccessible...
Monthly Orthopedic Fundraising
The overall value of the orthopedic market increases when companies obtain money from outside sources such as public market fundraising or grants. The goal of this feature is to track these fundrai...
Company Spotlight: Reflexion Health
.png)
Reflexion Health’s VERA (Virtual Exercise Rehabilitation Assistant) proposes a solution for common frustrations with the health care system. The company began nearly six years ago from a concept de...
The Race for a Robotics Ecosystem
Orthopedic manufacturers are racing to develop surgical robots for total joint arthroplasty (TJA) that promise improved outcomes, faster surgery, and fewer complications. Market opportunity for sur...
EyePoint Reports Q1-2019 Net Revenues for Yutiq, Dexycu
EyePoint Pharmaceuticals reported May 8 that its Q1-2019 net revenues totaled $2.0 million compared with $928 thousand in Q1-2018. The Watertown, Massachusetts company launched Yutiq (chronic non-i...
Want to Read the Full Article?
Already Have an Account?
Register A Corporate Account
A corporate accounts gives you access to licensed reports and subscriptions, the latest news, and a personalized dashboard.